GLPwatch

GLP-1R agonist liraglutide attenuates pain hypersensitivity by stimulating IL-10 release in a nitroglycerin-induced chronic migraine mouse model.

Neurosci Lett · 2023

Last updated 2026-05-28

In a mouse study of chronic migraine, the GLP-1 drug liraglutide reduced pain sensitivity and lowered levels of molecules linked to the condition in a brain region involved in pain processing. The drug also increased levels of a protein called IL-10, and giving IL-10 directly reduced pain sensitivity as well.

AI summary of the abstract below.

JournalNeurosci Lett, 2023
Citations18
Relative citation ratio2.72
NIH percentile82
Molecules liraglutide

Abstract

Glucagon-like peptide-1 receptor (GLP-1R) has been indicated to involve in chronic pain, however, the mechanism by which GLP-1R alleviates the central sensitization of chronic migraine (CM) remains unclear. Treatment with GLP-1R agonist liraglutide attenuated trigeminal allodynia and suppressed the protein levels of CM-associated molecules in the trigeminal nucleus caudalis (TNC). Further analysis showed that injection of liraglutide stimulated the release of IL-10 in the TNC. Treatment with IL-10 also alleviated pain hyperalgesia. Our findings illustrated that liraglutide might alleviate the central sensitization of CM by stimulating the release of IL-10, which reveals a novel mechanism of CM.

Verbatim abstract via PubMed 37442520 ↗

Related research